Who makes Buffered pantoprazole?

Buffered pantoprazole is developed by Abbott.

What development phase is Buffered pantoprazole in?

Buffered pantoprazole is FDA-approved (marketed).

What are the side effects of Buffered pantoprazole?

Common side effects include Headache, Diarrhea, Nausea, Abdominal pain, Flatulence, Rash.

Last reviewed 2026-04-22 · How we verify

Buffered pantoprazole

Abbott · FDA-approved active Small molecule

Buffered pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach.

Buffered pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.

At a glance

Generic name	Buffered pantoprazole
Also known as	ABT-897, Buffered Pantoprazole, Digene Total
Sponsor	Abbott
Drug class	Proton pump inhibitor (PPI)
Target	H+/K+-ATPase (proton pump)
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	FDA-approved

Mechanism of action

Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. The buffered formulation contains sodium bicarbonate to neutralize gastric acid in the stomach, allowing the pantoprazole to be absorbed in the small intestine where it is activated. This combination provides rapid symptom relief while the PPI provides sustained acid suppression.

Approved indications

Gastroesophageal reflux disease (GERD)
Peptic ulcer disease
Zollinger-Ellison syndrome
Prevention of NSAID-induced ulcers

Common side effects

Headache
Diarrhea
Nausea
Abdominal pain
Flatulence
Rash

Key clinical trials

Effect of Digene Total (Buffered Pantoprazole) on 24 Hour Gastric Potential Hydrogen (pH) in Patients From Acid Peptic Disorder After Single and Repeated Dosing. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Buffered pantoprazole CI brief — competitive landscape report
Buffered pantoprazole updates RSS · CI watch RSS
Abbott portfolio CI